Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06602232 · ClinicalTrials.gov registry record · Phase 1
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
A Phase 1 study of Alopecia Areata and Vitiligo, sponsored by Dren Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 20
- Study locations
NCT06602232: Recruiting Phase 1 study of Alopecia Areata and Vitiligo, sponsored by Dren Bio.
NCT06602232 is a Phase 1 study of Alopecia Areata and Vitiligo that is actively recruiting participants, run by Dren Bio. The registered enrollment target is 80 participants, below the 1,952-participant average among 26 other Alopecia Areata trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06602232, a Phase 1 study of Alopecia Areata and Vitiligo, is actively recruiting participants, sponsored by Dren Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
Conditions Studied
Interventions
- DRUG DR-01
Study Locations (20)
Other
- Dren Investigational Site - Auckland
- Dren Investigational Site - Christchurch
- Dren Investigational Site - Grafton
Indiana
- Dren Investigational Site - Indianapolis
- Dren Investigational Site - West Lafayette
Pennsylvania
- Dren Investigational Site - Philadelphia
- Dren Investigational Site - Pittsburgh
New South Wales
- Dren Investigational Site - Charlestown
- Dren Investigational Site - Darlinghurst
California
- Dren Investigational Site - Northridge
Florida
- Dren Investigational Site - Miami
Georgia
- Dren Investigational Site - Evans
Idaho
- Dren Investigational Site - Meridian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
What NCT06602232 shows while recruiting
NCT06602232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,952-participant average among 26 other Alopecia Areata trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Alopecia Areata appearing as the primary indexed condition, and to 1 intervention - of which DR-01 is the first listed.
NCT06602232 names 20 study sites across 15 states, led by Other, Indiana, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06602232 about?
NCT06602232 is a clinical study titled "A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo". This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
What is the current status of trial NCT06602232?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-10-30. Estimated completion is 2026-09.
What conditions does trial NCT06602232 study?
This clinical trial studies the following conditions: Alopecia Areata, Vitiligo.
What interventions are being tested in trial NCT06602232?
The interventions under investigation include: DR-01 (DRUG).
Who is sponsoring clinical trial NCT06602232?
This trial is sponsored by Dren Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06602232 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Idaho, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06602232's enrollment target sits among peer trials
80 15th of 26 higher than 12 of 26 other Alopecia Areata trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alopecia Areata trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
A Study of LAD603 in Adults With Alopecia Areata
RECRUITING · Phase 2
-
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
RECRUITING
-
Dupilumab in the Treatment of Pediatric Alopecia Areata
RECRUITING · Phase 2
-
Intralesional Cyclosporine for Alopecia Areata
RECRUITING · Early Phase 1
-
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI